Pharmaceutical

YouTube cracks down on misinformation on cancer treatment

YouTube’s health division is stepping up its effort to combat medical informatio...

STAT+: Pharmalittle: Amazon Pharmacy offers insulin dis...

Amazon Pharmacy will begin automatically applying manufacturer coupons to more t...

Radiation, a mainstay of cancer treatment, begins a fad...

“There are situations now on an individual patient basis where radiation may not...

STAT+: BMS, looking to build a market for a heart drug,...

As Bristol Myers Squibb works to build Camzyos into a blockbuster drug, it has p...

Patient advocates warn FDA proposal on salt intake coul...

Patient advocates are warning that a proposal from the FDA meant to reduce consu...

Opinion: Home blood pressure machines are often wrong. ...

These popular machines may be wildly inaccurate for people with wider or longer ...

House Democrats unveil new legislation that expands the...

In July, Democratic health leaders from the US House of Representatives proposed...

Botulinum battle heats up with FDA approving Daxxify fo...

Daxxify becomes the latest botulinum toxin to make the jump from aesthetics to t...

LifeArc invests nearly $10m in Crick Institute’s Africa...

The funding will extend support to the Institute’s Crick Africa Network for five...

Valneva pushes FDA approval date for chikungunya vaccine

The PDUFA date has been pushed by three months to November to allow for more tim...

Novartis acquires Chinook for $3.2bn to boost kidney di...

Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is ...

How the pharma industry can benefit from using modular ...

New advancements in cold chain monitoring are poised to revolutionise the pharma...

RNA-LNPs: Navigating the regulatory challenges

We discuss why demand for ionizable lipid mixes for delivery and target validati...

ImPact enters partnership for pathologic myopia therapy...

ImPact Biotech entered into a partnership with Maastricht University to develop ...

Biopharma firm Zetagen raises $9.79m in Series B financ...

Zetagen Therapeutics raised $9.79m in a Series B funding round to develop treatm...

vTv announces Phase III plans for type 1 diabetes drug ...

vTv plans to initiate a Phase III study for cadisegliatin with an FDA-recommende...